Health & bio
Novo Nordisk's Wegovy Captures 65% Share of New GLP-1 Prescriptions
Novo Nordisk's Wegovy commands 65% of new GLP-1 obesity drug prescriptions in the United States, extending market dominance.
Primary sources · 1
Novo Nordisk's Wegovy commands 65% of new GLP-1 obesity drug prescriptions in the United States, extending market dominance.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.